一周一次的C型天然尿素用于治疗心力衰竭,使用保存的喷射分数治疗心力衰竭
Anne Louise Bank Kodal1, Jakob Ewald1, Christian Poulsen1
1Research and Development, Novo Nordisk A/S, Maaloev DK-2760, Denmark.
Journal of medicinal chemistry
|December 11, 2025
概括
一种新型的C型尿素 (CNP) 模拟物65,显示出治疗心力衰竭的前景,使用保存的喷射分数 (HFpEF). 它的设计增强了稳定性和生物可用性,可以有效地每周进行皮下输送.
科学领域:
- 心血管药理学心血管药理学
- 药物设计和开发 药物设计和开发
背景情况:
- C型性尿素 (CNP) 为心力衰竭提供了治疗效益,具有保存的喷射分数 (HFpEF).
- 现有的CNP类型药物面临着稳定性和使用频率方面的挑战.
研究的目的:
- 在HFpEF中设计一种新型的CNP类似物 (65) 用于每周一次的皮下注射.
- 为了优化药物动力学特性,化学稳定性和皮下生物可用性.
主要方法:
- 设计了一个CNP类型 (65) 具有五个战略替代和脂肪酸延伸器.
- 修改了同电点 (pI),以增强皮下输送和减少注射部位反应.
- 在pH 6.5的液体配方中评估稳定性,并进行了体内评估.
主要成果:
- 同类型65在每周服用时显示出有利的药理动力学特征.
- 与高PI CNP类似物相比,获得了改善的皮下生物可用性.
- 在HFpEF模型中证实脂肪酸衍生低PI CNP类型的治疗潜力.
结论:
- 工程 CNP 类型 65 显示了每周通过皮下注射进行有效的 HFpEF 治疗的潜力.
- 低pI和脂肪酸衍生是改善CNP模拟性能的关键策略.
- 模拟65正在进入第一阶段的临床试验.
相关概念视频
Heart Failure V: Medical Management
198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Heart Failure II: Pathophysiology
668
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
668
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424


